Meta reportedly takes more talent from OpenAI.
Researchers Jason Wei and Hyung Won Chung are said to be joining Meta's superintelligence lab, the latest of several high-profile OpenAI researchers and developers to be plucked by the social media giant. That would make this the second big move in as many years for Wei and Won Chung, who left Google's Brain research group to join OpenAI in 2023.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Clear Fork Solar Deal Fuels Meta and Enbridge
Meta (NASDAQ:META) lands a $900 million boost for its Clear Fork solar project in Texas thanks to Enbridge's investment. Enbridge (NYSE:ENB) will fund 600 MW of solar capacity, cementing a long?term deal for Meta to buy 100 % of the green power for its data centers. The project, slated to go live by 2027 near San Antonio, reflects a broader tech pivot toward renewable energy to power AI and cloud operations. Enbridge says Clear Fork will add accretive cash flow and earnings once online. META stock has climbed 21 % this year, while ENB shares are up 9 % on the back of growing clean?energy investments. Clear Fork demonstrates the growing demand for renewable power across North America from blue?chip companies involved in technology and data center operations, Enbridge said in a release. Meta joins Apple (NASDAQ:AAPL), Google (NASDAQ:GOOG) and Microsoft (NASDAQ:MSFT) in signing long?term power purchase agreements as AI workloads surge and sustainability targets tighten. This article first appeared on GuruFocus.
Yahoo
27 minutes ago
- Yahoo
AstraZeneca Announces $50B US Investment Amid Pharma Tariff Threat
AstraZeneca (AZN, Financials) said Monday it will invest $50 billion in the United States by 2030 to expand manufacturing and research, positioning itself ahead of potential import tariffs under President Donald Trump's administration. The British-Swedish pharmaceutical firm said the plan includes building a new manufacturing facility in Virginiaits largest single capital outlay in 26 yearsand expanding operations across Maryland, Massachusetts, California, Indiana, and Texas. The spending will also support AstraZeneca's U.S. clinical trial supply network and development of weight-loss and cardiovascular drugs. CEO Pascal Soriot unveiled the plan in Washington, calling for other countries to pay more for drugs to balance global research funding. The United States cannot build or carry the cost of R&D for the entire world, he said. The company aims to reach $80 billion in annual revenue by 2030, with half of that coming from the U.S., which already accounted for over 40% of sales in 2024. The move follows similar announcements from Roche (ROG, Financials), Eli Lilly (LLY, Financials), Johnson & Johnson (JNJ, Financials), Novartis (NOVN, Financials), and Sanofi (SASY, Financials). Commerce Secretary Howard Lutnick said the plan aligns with Trump's push to reduce reliance on foreign-made drugs. Our nation's new tariff policies are focused on ending this structural weakness, he said in a statement released by the company. AstraZeneca said the investment could add tens of thousands of new jobs. The company employs around 18,000 people in the U.S. and 90,000 globally. The pledge builds on $3.5 billion in investments announced last year and comes as the company evaluates a possible shift in its stock listing from London to New York. This article first appeared on GuruFocus.
Yahoo
27 minutes ago
- Yahoo
Tesla Settles Lawsuit Over Louisiana's Direct Sales Ban Ask ChatGPT
Tesla (TSLA, Financials) has reached a settlement with Louisiana officials and auto dealer groups, ending a years-long legal fight over the state's 2017 ban on direct-to-consumer sales. In a motion filed Monday in New Orleans federal court, the company said its claims had been fully and finally resolved. The case targeted state regulators and dealership commissioners, accusing them of using their positions to undermine Tesla's sales model, which avoids traditional franchised dealers. Tesla also challenged state restrictions on leasing and servicing its vehicles. While a lower court initially dismissed the case, a federal appeals court revived Tesla's due process claim and antitrust challenge in 2024. The U.S. Supreme Court declined to hear a final appeal from Louisiana commissioners last month. This article first appeared on GuruFocus.
